EA201890623A1 - Рациональная комбинированная терапия для лечения рака - Google Patents
Рациональная комбинированная терапия для лечения ракаInfo
- Publication number
- EA201890623A1 EA201890623A1 EA201890623A EA201890623A EA201890623A1 EA 201890623 A1 EA201890623 A1 EA 201890623A1 EA 201890623 A EA201890623 A EA 201890623A EA 201890623 A EA201890623 A EA 201890623A EA 201890623 A1 EA201890623 A1 EA 201890623A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- agents
- cancer treatment
- combined therapy
- rational
- rational combined
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 108010006519 Molecular Chaperones Proteins 0.000 abstract 2
- 102000005431 Molecular Chaperones Human genes 0.000 abstract 2
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 abstract 1
- 229940121649 protein inhibitor Drugs 0.000 abstract 1
- 239000012268 protein inhibitor Substances 0.000 abstract 1
- 230000008707 rearrangement Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237470P | 2015-10-05 | 2015-10-05 | |
| PCT/US2016/055594 WO2017062520A1 (en) | 2015-10-05 | 2016-10-05 | Rational combination therapy for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201890623A1 true EA201890623A1 (ru) | 2018-09-28 |
Family
ID=57145064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201890623A EA201890623A1 (ru) | 2015-10-05 | 2016-10-05 | Рациональная комбинированная терапия для лечения рака |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20180280397A1 (enExample) |
| EP (1) | EP3359196B1 (enExample) |
| JP (1) | JP7132848B2 (enExample) |
| KR (1) | KR20180058824A (enExample) |
| CN (1) | CN108472376A (enExample) |
| AU (1) | AU2016336351A1 (enExample) |
| BR (1) | BR112018006572A2 (enExample) |
| CA (1) | CA3000851A1 (enExample) |
| EA (1) | EA201890623A1 (enExample) |
| IL (1) | IL258494A (enExample) |
| MA (1) | MA47474A (enExample) |
| MX (1) | MX2018004112A (enExample) |
| TW (1) | TW201722422A (enExample) |
| WO (1) | WO2017062520A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3086792B1 (en) | 2013-12-23 | 2022-10-12 | Memorial Sloan-Kettering Cancer Center | Methods and reagents for radiolabeling |
| CN110090303B (zh) * | 2019-05-07 | 2022-09-16 | 浙江大学 | 阿片受体激动剂在制造用于治疗恶性肿瘤的药物中的用途 |
| CN112641949A (zh) * | 2021-01-11 | 2021-04-13 | 深圳市人民医院(深圳市呼吸疾病研究所) | 一种含有pi3k抑制剂的药物组合物及其应用 |
| US20240371465A1 (en) * | 2023-05-02 | 2024-11-07 | National Central University | Method, system, and computer readable medium for post-translational modifications detection |
| CN116813622A (zh) * | 2023-05-19 | 2023-09-29 | 中国科学院基础医学与肿瘤研究所(筹) | 一种基于分子伴侣hsp90介导的靶向降解gpx4的嵌合体及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1337275A4 (en) | 2000-11-02 | 2007-05-09 | Sloan Kettering Inst Cancer | METHOD FOR ENHANCING THE EFFICACY OF CYTOTOXIC AGENTS USING HSP 90 INHIBITORS |
| US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US10336757B2 (en) | 2006-06-30 | 2019-07-02 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases through inhibition of HSP90 |
| CN108752280A (zh) | 2009-08-17 | 2018-11-06 | 纪念斯隆-凯特琳癌症中心 | 热休克蛋白结合化合物、组合物以及其制备和使用方法 |
| AU2010303343B2 (en) | 2009-10-07 | 2015-11-19 | Sloan-Kettering Institute For Cancer Research | Purine derivatives useful as HSP90 inhibitors |
| KR102010222B1 (ko) | 2011-04-05 | 2019-08-13 | 슬로안-케테링인스티튜트퍼캔서리서치 | Ｈｓｐ９０ 억제제 |
| CA2832099C (en) | 2011-04-05 | 2019-07-09 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| CN104081203B (zh) | 2011-07-08 | 2018-07-31 | 索隆-基特林癌症研究协会 | 标记的hsp90抑制剂的用途 |
| CA2921571C (en) | 2013-08-16 | 2022-04-05 | Memorial Sloan-Kettering Cancer Center | Selective grp94 inhibitors and uses thereof |
| AU2015259173B2 (en) | 2014-05-13 | 2019-09-05 | Memorial Sloan Kettering Cancer Center | Hsp70 modulators and methods for making and using the same |
-
2016
- 2016-10-05 BR BR112018006572A patent/BR112018006572A2/pt not_active Application Discontinuation
- 2016-10-05 JP JP2018536719A patent/JP7132848B2/ja active Active
- 2016-10-05 TW TW105132272A patent/TW201722422A/zh unknown
- 2016-10-05 MA MA047474A patent/MA47474A/fr unknown
- 2016-10-05 US US15/765,980 patent/US20180280397A1/en not_active Abandoned
- 2016-10-05 EP EP16782374.9A patent/EP3359196B1/en active Active
- 2016-10-05 AU AU2016336351A patent/AU2016336351A1/en not_active Abandoned
- 2016-10-05 EA EA201890623A patent/EA201890623A1/ru unknown
- 2016-10-05 CN CN201680069308.9A patent/CN108472376A/zh active Pending
- 2016-10-05 KR KR1020187012285A patent/KR20180058824A/ko not_active Withdrawn
- 2016-10-05 WO PCT/US2016/055594 patent/WO2017062520A1/en not_active Ceased
- 2016-10-05 MX MX2018004112A patent/MX2018004112A/es unknown
- 2016-10-05 CA CA3000851A patent/CA3000851A1/en not_active Abandoned
-
2018
- 2018-04-04 IL IL258494A patent/IL258494A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA47474A (fr) | 2019-12-25 |
| WO2017062520A1 (en) | 2017-04-13 |
| AU2016336351A1 (en) | 2018-05-10 |
| JP2018537519A (ja) | 2018-12-20 |
| EP3359196A1 (en) | 2018-08-15 |
| IL258494A (en) | 2018-05-31 |
| MX2018004112A (es) | 2018-06-20 |
| EP3359196B1 (en) | 2022-03-16 |
| TW201722422A (zh) | 2017-07-01 |
| JP7132848B2 (ja) | 2022-09-07 |
| KR20180058824A (ko) | 2018-06-01 |
| BR112018006572A2 (pt) | 2018-10-09 |
| CN108472376A (zh) | 2018-08-31 |
| CA3000851A1 (en) | 2017-04-13 |
| US20180280397A1 (en) | 2018-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| PH12017501818A1 (en) | Fgfr/pd-1 combination therapy for the treatment of cancer | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| PH12018502429A1 (en) | Antibody molecules for cancer treatment | |
| BR112015021115A2 (pt) | agentes para induzir apoptose para o tratamento de câncer e doenças imunes e autoimunes | |
| MX2017005258A (es) | Terapia combinada para tratamiento de enfermedad. | |
| MX391159B (es) | Proteínas de unión al antígeno anti-tigit y métodos para usarlas | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| EA201691079A1 (ru) | Комбинированная терапия для лечения онкологического заболевания | |
| BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
| EA201791867A1 (ru) | Бициклические гетероциклы как ингибиторы fgfr4 | |
| MX373045B (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| BR112018008503A2 (pt) | método para tratar câncer de pulmão de células pequenas, método para tratar um sujeito, método para selecionar um sujeito com câncer | |
| UA109278C2 (uk) | Лікарські засоби, які індукують апоптоз, для лікування раку і імунних і аутоімунних захворювань | |
| CO2017004932A2 (es) | Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva | |
| BR112017010761A2 (pt) | tratamento de doenças associadas à ativação de célula estrelada hepática com o uso de terapias de redução de amônia | |
| MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
| MX2018005348A (es) | Composiciones y metodos para transduccion de tumores. | |
| EA201890623A1 (ru) | Рациональная комбинированная терапия для лечения рака | |
| BR112017018198A2 (pt) | inibição da atividade de olig2 | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| MX380835B (es) | Terapia de combinación pac-1. | |
| EA202090270A1 (ru) | Новые замещенные производные ксантина |